评估鞘内注射奥那西诺基因阿贝帕伏韦-brve(OAV101B)(ITVISMA®)治疗脊髓性肌萎缩症参与者的真实世界安全性与有效性:一项美国实用多中心研究(STREAM)
Onasemnogene Abeparvovec:评估接受鞘内注射Onasemnogene Abeparvovec-brve(ITVISMA®)治疗的脊髓性肌萎缩症参与者的真实世界安全性与有效性:一项美国实用多中心研究(STREAM)
The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).
研究概览
详细说明
STREAM is a prospective, multicentre cohort study that will follow U.S. participants with genetically confirmed SMA who receive a single, intrathecal dose of onasemnogene abeparvovec-brve. All eligible participants are enrolled prior to therapeutic injection. No randomisation, blinding, or placebo control is employed; instead, each participant acts as his or her own baseline comparator. This study will use an exploratory external cohort of patients matched by age, clinical characteristics, treatment history and availability of at least 1 year of pre-treatment medical history. This patient cohort will be based on a database of retrospectively collected electronic medical records data and will be used descriptively to contextualize study outcomes. Bias is minimised through pre-specified endpoints, uniform rater training on motor-function scales, and a detailed statistical analysis plan that stipulates handling of missing data and intercurrent events in advance.
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Novartis Pharmaceuticals
- 电话号码:1-888-669-6682
- 邮箱:novartis.email@novartis.com
研究联系人备份
- 姓名:Novartis Pharmaceuticals
学习地点
-
-
Arkansas
-
Little Rock、Arkansas、美国、208833
- 招聘中
- Arkansas Children's Hospital
-
首席研究员:
- Aravindhan Veerapandiyan
-
接触:
- Buffy Gofforth
- 电话号码:(501) 364-1591
-
-
California
-
Stanford、California、美国、94305-5235
- 招聘中
- Stanford Hospital
-
接触:
- 电话号码:(650) 725-4341
- 邮箱:NeuromuscularResearch@stanford.edu
-
首席研究员:
- John W Day
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 招聘中
- Boston Childrens Hospital
-
接触:
- Maggie Allen
- 电话号码:(617) 919-3554
- 邮箱:Maggie.Allen@childrens.harvard.edu
-
首席研究员:
- Leslie Hayes
-
-
New York
-
New York、New York、美国、10032
- 招聘中
- Columbia University Medical Center
-
首席研究员:
- Claudia Chiriboga
-
接触:
- Kimberly Berry
- 电话号码:212-342-3038
- 邮箱:kb2996@cumc.columbia.edu
-
-
Ohio
-
Columbus、Ohio、美国、43210
- 招聘中
- Ohio State University Medical Center
-
首席研究员:
- Bakri Elsheikh
-
接触:
- Georgia (Gia) Cinkay
- 电话号码:(614) 366-9050
- 邮箱:Georgia.cinkay@osumc.edu
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、209277
- 招聘中
- University of Pennsylvania
-
首席研究员:
- Lauren Elman
-
接触:
- Amanda (Mandy) Hicks
- 电话号码:(267) 496-3772
- 邮箱:amanda.hicks@pennmedicine.upenn.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
A participant will be enrolled in STREAM only if all the following conditions are met:
-
The participant has a genetically confirmed diagnosis of SMA (biallelic SMN1 deletion or mutation).
-
He or she is ≥ 2 years of age on the day of the intrathecal injection.
-
The treating Investigator intends to administer within the current episode of care, a single dose of ITVISMA® (1.2 × 10¹⁴ vg) in routine U.S. practice after written informed consent obtained.
-
One of the following functional categories applies at screening:
- independently ambulatory child/adolescent 2 - <18 years; or
- independently ambulatory adult (≥ 18 years).
- non-ambulatory (includes walkers with assistance) adult > 18 years with entry level RULM at baseline
-
At least 1 year of pre-treatment medical history, including motor-function documentation, can be retrieved from the site electronic record.
Key Exclusion Criteria:
A participant will be excluded if any of the following conditions apply:
- Contraindication for lumbar puncture as determined by the investigator (e.g., spinal anatomy that precludes safe lumbar puncture)
- An uncontrolled acute illness, active infection, febrile illness or acute medical condition, within 30 days prior to dosing
- Inability to tolerate corticosteroids administered by mouth or gastrostomy tube
- Current participation in another interventional clinical trial that would interfere with the objectives or endpoints of STREAM. Note: participation in observational cohort studies or non-interventional studies in which the participant does not receive treatment or undergo procedures which may compromise this study data integrity may be allowed following Sponsor approval
- Planned relocation or any circumstance that is likely to prevent completion of the minimum 12-month follow-up.
Other protocol inclusion, exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Onasemnogene Abeparvovec-brve
Participants with spinal muscular atrophy, including:
|
administered once via lumbar puncture with systemic corticosteroid prophylaxis per label.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in HFMSE for independently ambulatory participants
大体时间:Baseline, 6, 12, 18 and 24 months
|
The HFMSE is a validated SMA specific assessment devised for use in children with SMA to give objective information on motor ability and clinical progression. The HFMSE contains 33 items rated from 0 (unable to perform) to 2 (performs without modification/adaptation/compensation). Total scores range from 0-66. Higher scores indicate higher levels of motor ability. |
Baseline, 6, 12, 18 and 24 months
|
|
Change from baseline in RULM for non-ambulatory (including walkers with assistance) participants
大体时间:Baseline, 6, 12, 18 and 24 months
|
The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-ambulatory (including walkers with assistance) individuals with SMA. The scale consists of 19 scorable items: 18 items scored on 0 (unable) to 2 (full achievement) scale, and one item that is scored from 0 (unable) to 1 (able). Total scores range from 0-37 points. Higher scores reflect higher level of motor ability. |
Baseline, 6, 12, 18 and 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:up to 5 years
|
Incidence of AEs and SAEs, including changes in laboratory tests and procedure-related events qualifying and reported as AEs. |
up to 5 years
|
|
Modified SMA Functional Rating Scale (SMA-FRS) for independently ambulatory participants (≥ 18 years of age) and non-ambulatory particpants
大体时间:Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5
|
Modified Spinal Muscular Atrophy Functional Rating Scale (SMAFRS): Ten items address questions related to eating, upper extremity dressing, lower extremity dressing, grooming, bathing, toileting, turning in bed and adjusting bed clothes, transfers, walking, and climbing stairs. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. |
Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5
|
|
Assessment of Caregiver Experience with Neuromuscular Disease (ACEND) for independently ambulatory participants (<18 years of age)
大体时间:Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
The Assessment of Caregiver Experience with Neuromuscular Disease (ACEND): quantifies caregivers' perceptions of function and quality of life pertaining to time, finance and emotion. The ACEND was developed and validated to specifically assess caregiver impact experienced by raising children severely affected by neuromuscular diseases. While specifically developed for application to caregivers of patients undergoing orthopedic surgery, it has application to those with SMA. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. |
Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
|
Subgroup outcomes: Hammersmith Functional Motor Scale Expanded (HFMSE)
大体时间:Baseline, 6, 12, 18 and 24 months
|
Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The HFMSE is a validated SMA specific assessment to give objective information on motor ability and clinical progression. Total scores range from 0-66. Higher scores indicate higher levels of motor ability. |
Baseline, 6, 12, 18 and 24 months
|
|
Subgroup outcomes: Revised Upper Limb Module (RULM)
大体时间:Baseline, 6, 12, 18 and 24 months
|
Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-independent ambulatory individuals with SMA. Total scores range from 0-37 points. Higher scores reflect higher level of motor ability. |
Baseline, 6, 12, 18 and 24 months
|
|
Frequency of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
大体时间:Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
Assessment of SMA-related healthcare-resource utilisation. |
Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
|
Duration of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
大体时间:Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
Assessment of SMA-related healthcare-resource utilisation. |
Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
|
Cobb angle
大体时间:Baseline, up to 24 months
|
Assessment of scoliosis progression as a disease-progression marker. |
Baseline, up to 24 months
|
|
Daily hours of respiratory support (none, non-invasive ventilation, invasive ventilation)
大体时间:Baseline, up to 24 months
|
Assessment of respiratory function as a disease-progression marker. |
Baseline, up to 24 months
|
|
Joint-range limitation measured by goniometer
大体时间:Baseline, up to 24 months
|
Assessment of evolution of joint contractures as a disease-progression marker. |
Baseline, up to 24 months
|
|
Nutritional-support category (oral, gastrostomy feeds, total parenteral nutrition)
大体时间:Baseline, up to 24 months
|
Assessment of nutrition status as a disease-progression marker. |
Baseline, up to 24 months
|
|
6-Minute Walk Test (6MWT) for ambulatory patients
大体时间:Baseline, Months 6, 12, 18, and 24
|
To assess disease-progression markers. 6MWT: distance in metres; greater distance indicates better ambulatory capacity. |
Baseline, Months 6, 12, 18, and 24
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- COAV101B1US01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.